✦ LIBER ✦

Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer

✍ Scribed by Gianluca Masi; Samanta Cupini; Lorenzo Marcucci; Elisa Cerri; Fotios Loupakis; Giacomo Allegrini; Isa Maura Brunetti; Elisabetta Pfanner; Maurizio Viti; Orlando Goletti; Franco Filipponi; Alfredo Falcone

Book ID: 119986751
Publisher: Springer
Year: 2006
Tongue: English
Weight: 611 KB
Volume: 13
Category: Article
ISSN: 1068-9265
DOI: 10.1245/aso.2006.03.094

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Liver resection after irinotecan, 5-fluo

Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases

✍ Wing M. Ho; B. Ma; Tony Mok; W. Yeo; Paul Lai; R. Lim; Jane Koh; Y. Y. Wong; Ann 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 80 KB

FCGR2AandFCGR3Apolymorphisms and clinica

FCGR2AandFCGR3Apolymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

✍ Kjersem, Janne B; Skovlund, Eva; Ikdahl, Tone; Guren, Tormod; Kersten, Christian 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 384 KB

Safety and efficacy of second-line treat

Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer

✍ Xie, Song; Han, Guoping; Fan, Zhikun; He, Lifeng; Xu, Wenbing; Qin, Zhen 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 253 KB

Cetuximab in combination with irinotecan

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

✍ Jean-Luc Raoul; Jean-Luc Van Laethem; Marc Peeters; Catherine Brezault; Fares Hu 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 890 KB

Bevacizumab in association with de Gramo

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer : A single-center phase 2 trial

✍ Bruno Vincenzi; Daniele Santini; Antonio Russo; Chiara Spoto; Olga Venditti; Sim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5‐fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. ## METHODS: The authors included 48 heavily pretreated pati

Dose escalating study of cetuximab and 5

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

✍ Gunnar Folprecht,Susanne Hamann,Katharina Schütte,Tanja Trarbach… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 460 KB